



## NEWS RELEASE

### **For Further Information Contact:**

Roy Wolvin

Nymox Pharmaceutical Corporation

800-93NYMOX

[www.nymox.com](http://www.nymox.com)

### **For Immediate Release:**

## **Nymox's NX-1207 To Be Clinically Tested for Prostate Cancer**

### **Company Announces Positive NX-1207 Results in Preclinical Studies of Human Prostate Carcinoma**

HASBROUCK HEIGHTS, NJ (October 14, 2009) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that NX-1207, the Company's lead drug in development, has been shown to produce strongly positive and repeatable results in laboratory studies of human prostate cancer. In addition, local injection of NX-1207 showed activity in animals with transplanted human prostate carcinoma. The NX-1207 used in these studies is a different formulation and a much higher dosage from that of NX-1207 used to treat benign prostatic hyperplasia (BPH).

NX-1207 has been tested in humans since 2003 for benign prostatic hyperplasia (BPH), and has been shown thus far to have an excellent safety profile, with no known serious drug side effects seen in studies to date. The laboratory studies of prostate cancer were conducted over a 2 year period, using human prostate cancer cell lines and numerous different standard well established methods.

The Company intends to advance NX-1207 into human clinical trials for the focal treatment of localized prostate cancer.

Prostate cancer is the most common cancer in men. The American Cancer Society estimates that in 2009 alone an estimated 192,280 men in the U.S. will be newly diagnosed with prostate cancer and 27,360 will die from it. It is estimated that some 1.8 million American men are living with a diagnosis of prostate cancer. Approximately 90 percent of prostate cancers are confined to the prostate gland and thus potential candidates for localized treatment. Men diagnosed with localized prostate cancer face difficult choices ranging from watchful waiting (active surveillance) with no treatment to one of the several current methods of treatment most of which have side effects.

More information on the NX-1207 program's tumor results will be presented at a later date.

NX-1207 is a novel drug developed by Nymox which is in Phase 3 development for the treatment of BPH. The drug has been successful in a series of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs. NX-1207 is administered by a urologist in an office procedure that takes only a few minutes and involves little or no pain or discomfort. Patients notice improvement as early as a week or two after treatment. Follow-up studies have shown that many men showed continued benefit from a single NX-1207 treatment for 2 years or more. NX-1207 treatment does not require the patient to take pills daily for the rest of his life, like currently approved BPH medications, and does not have the side effects associated with approved drugs which can include sexual dysfunction, dizziness and other adverse reactions.

BPH is one of the most commonly diagnosed diseases in the U.S. adult male population. Up to 46% of men between the ages of 40 and 79 suffer from moderate to severe urinary problems and symptoms associated with BPH. The condition can seriously impact health and quality of life and can lead to urinary retention, incontinence, and other serious consequences.

More information about Nymox is available at [www.nymox.com](http://www.nymox.com), email: [info@nymox.com](mailto:info@nymox.com), or 800-936-9669.

*This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.*

###